Ocular Therapeutix (OCUL) Competitors

Ocular Therapeutix (NASDAQ:OCUL) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, community ranking, earnings, dividends and profitability.

Do analysts recommend OCUL or GRFS?

Ocular Therapeutix currently has a consensus price target of $16.38, suggesting a potential upside of 113.11%. Given Ocular Therapeutix's higher probable upside, equities research analysts plainly believe Ocular Therapeutix is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Grifols	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Which has preferable valuation and earnings, OCUL or GRFS?

Grifols has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$63.72M	19.18	-$80.74M	-$1.26	-6.10
Grifols	$7.21B	0.69	$64.20M	$1.17	6.23

Does the media favor OCUL or GRFS?

In the previous week, Grifols had 1 more articles in the media than Ocular Therapeutix. MarketBeat recorded 4 mentions for Grifols and 3 mentions for Ocular Therapeutix. Grifols' average media sentiment score of 1.36 beat Ocular Therapeutix's score of 0.70 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is OCUL or GRFS more profitable?

Grifols has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -283.74%. Grifols' return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-283.74%	-45.18%	-30.87%
Grifols	N/A	N/A	N/A

Does the MarketBeat Community believe in OCUL or GRFS?

Ocular Therapeutix received 92 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 70.27% of users gave Ocular Therapeutix an outperform vote while only 56.09% of users gave Grifols an outperform vote.

Company	Underperform	Outperform
Ocular Therapeutix	Outperform Votes 442 70.27%	Underperform Votes 187 29.73%
Grifols	Outperform Votes 350 56.09%	Underperform Votes 274 43.91%

Which has more risk and volatility, OCUL or GRFS?

Ocular Therapeutix has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in OCUL or GRFS?

59.2% of Ocular Therapeutix shares are held by institutional investors. 3.5% of Ocular Therapeutix shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Grifols beats Ocular Therapeutix on 11 of the 19 factors compared between the two stocks.